Arcutis Biotherapeutics, Inc.
ARQT
Clasificación en acciones
#3980
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Precio por acción
$32.88
Última sincronización: 2026-10-20
Capitalización bursátil
$4.13B
Cambio (1 día)
3.11%
Cambio (1 año)
59.32%
País
US
Comercio Arcutis Biotherapeutics, Inc. (ARQT)
Categoría
Healthcare
Ingresos de Arcutis Biotherapeutics, Inc. (ARQT)
Ingresos en Jun 2026 TTM: $463.98M
Según los últimos informes financieros de Arcutis Biotherapeutics, Inc., los ingresos actuales de la empresa (TTM) son $463.98M. En 2023, la empresa obtuvo unos ingresos de $59.61M un aumento con respecto a los ingresos del año 2022, que fueron de $3.69M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Arcutis Biotherapeutics, Inc. desde 2017 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $463.98M | 136.07% |
| 2024 | $196.54M | 229.74% |
| 2023 | $59.61M | 1,517.09% |
| 2022 | $3.69M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 2,620.87% |
US
|
|
| $2.23B | 380.19% |
US
|
|
| $15.74B | 3,293.31% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,197.74% |
NL
|
